our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
AMHR2 expression
i
Other names: Anti-Mullerian Hormone Receptor Type 2, MISRII, MISR2, Muellerian Inhibiting Substance Type II Receptor, Anti-Muellerian Hormone Type II Receptor, Anti-Muellerian Hormone Type-2 Receptor, AMH Type II Receptor, MIS Type II Receptor, AMHR, MRII, Mullerian Inhibiting Substance Type II Receptor, Anti-Mullerian Hormone Receptor, Type II, Anti-Mullerian Hormone Receptor Type II, AMHR2
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Using a dual fluorescence reporter line, the membrane-targeted tdTomato (mT)/membrane-targeted EGFP (mG) mouse, we provided evidence that Sertoli cells transdifferentiated toward a granulosa cell fate during tumorigenesis. Thus, our findings indicate that Sertoli cell-specific activation of TGFBR1 leads to the formation of TGCTs, supporting a key contribution of Sertoli cell reprogramming to the development of this testicular malignancy in our model.
The cytokine profile of Amhr2 tumor-bearing mice is altered and their tumors express less immune checkpoint markers programmed-cell-death 1 (PD1) and cytotoxic T lymphocyte-associated protein 4 (CTLA4). Taken together, these data suggest that the AMH/AMHR2 axis plays a critical role in regulating the pro-tumoral function of CAMCs in ovarian cancer.
8 months ago
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • AMHR2 (Anti-Mullerian Hormone Receptor Type 2)
The AMH-AMHR2 axis mediates paracrine signaling between cancer cells and CAMCs within the tumor microenvironment to promote tumor growth and immune evasion. These results suggest that AMHR2 could be a highly specific target to enhance immunotherapies in ovarian cancer.
1 year ago
IO biomarker
|
CCNE1 (Cyclin E1) • AMHR2 (Anti-Mullerian Hormone Receptor Type 2)
MIS/AMH inhibits the growth of MIS/AMH receptor-expressing endometrial cancer cells through regulation of autophagy, apoptosis, and cell cycle pathways, as well as inhibition of Wnt signaling pathways. These data suggest that MIS/AMH functions as a tumor suppressor and may be an effective therapeutic agent in endometrial cancer.